• Lynparza gets FDA approval for ovarian cancer pharmatimes
    December 21, 2018
    AstraZeneca and MSD have announced that Lynparza (olaparib) has been given the green light by the FDA for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer, further expanding the drug's reach.
PharmaSources Customer Service